BETA
Your AI-Trained Oncology Knowledge Connection!
Stay up to date on recent advances in the multidisciplinary approach to cancer.
BMS-986279 Shows Feasibility as Non-Invasive fuc-GM1 Assessment in ES-SCLC
Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.
Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Certepetide Displays Positive Efficacy Trend in Metastatic PDAC
Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.
PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management
Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.
Tigilanol Tiglate Exhibits Positive Efficacy in Soft Tissue Sarcoma
Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.
21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
